The tumor vasculature is essential for tumor growth and survival and is a key target for anticancer therapy.
Introduction
Tumor growth and survival is dependent on the supply of nutrients and oxygen provided by blood vessels within the cancer; thus, eliminating the tumor vasculature is a key target for anticancer therapy (1) . Glioblastoma multiforme, the most malignant form of brain tumor, is highly vascular and contains abnormal vessels, unlike blood vessels found in normal brain (2) . We previously showed that primary cultures of human brain endothelial cells derived from blood vessels of malignant glioma tissues (TuBEC) are physiologically and functionally different from endothelial cells derived from nonmalignant brain tissues (BEC). TuBEC show consistent resistance to cell death with treatment of a wide range of chemotherapeutic agents (3, 4) . This chemoresistance of TuBEC has significant clinical consequences representing a major obstacle toward eradicating residual brain tumor and possibly causing disease recurrence.
The unfolded protein response (UPR) is an evolutionarily conserved mechanism that activates both proapoptotic and survival pathway to allow eukaryotic cells to adapt to endoplasmic reticulum (ER) stress (5) . A major UPR protective response is the induction of the ER chaperone protein GRP78/BIP, which is required for the proper folding and assembly of membrane and secretory proteins (5, 6) . GRP78 is up-regulated under stress conditions, such as glucose deprivation, hypoxia, or the presence of toxic agents (5, 7) . Overexpression of GRP78 is prominent in a wide variety of tumors and protects tumor cells against ER stress as well as a range of cancer therapeutic agents (8, 9) . The potential mechanisms responsible for this protection include preventing protein misfolding, binding of ER Ca 2+ , and blocking activation of caspases and proapoptotic proteins associated with the ER (9-13). Down-regulating GRP78 has been shown to reverse these cytoprotective effects (9) . Despite extensive studies on tumor cells, the expression and function of GRP78 in the tumor vasculature, an integral component of the cancer, has not been reported.
In this study, we showed that GRP78 is generally highly elevated in the tumor vasculature, both in situ in tissue and in vitro in primary cell cultures, in contrast to the minimal expression in normal brain. Knockdown of GRP78 by small interfering RNA (siRNA) significantly sensitized TuBEC to a variety of chemotherapeutic agents, whereas up-regulation of GRP78 in BEC renders these cells drug resistant. Recently, it was discovered that the green tea component (À)-epigallocatechin gallate (EGCG) blocks the ATPase domain of GRP78 and suppresses its antiapoptotic property (14) . We showed here that EGCG mimicked siRNA against GRP78 in sensitizing TuBEC to chemotherapeutic agents, providing proof of principle that small molecules targeting GRP78 will enhance the efficacy of chemotherapeutic drugs by eliminating the chemoresistant tumor vasculature.
Results

GRP78 Expression Is Generally Highly Elevated in Human Tumor-Associated Brain Endothelial Cells
To study the expression and function of GRP78 protein in the glioma vasculature, purified human primary cultures of TuBEC were examined; BEC served as the control. Due to the heterogeneity inherent in human specimens, 10 specimens from BEC and TuBEC each were examined by immunostaining with anti-GRP78 antibody. Representative staining of two different TuBEC patient samples and two different BEC specimens is shown in Fig. 1A . The intensity of GRP78 staining for all 20 specimens was evaluated; the results are summarized graphically and exhibit significant differences (P < 0.001) in intensity (Fig. 1B) . Thus, the staining results show that despite some variations among the individual cells, TuBEC specimens show strong positive staining for GRP78 compared with the faintly positive cells observed in BEC samples. To quantitate differences in GRP78 protein levels, Western blots were done on TuBEC specimens from two patients and two BEC specimens (Fig. 1C) . These results show that GRP78 protein expression in TuBEC is 3-to 4-fold higher compared with BEC.
To determine whether this in vitro observation is valid in situ, in the vasculature of tumor tissues, frozen sections of gliomas were immunostained for either GRP78 (red) or the endothelial cell marker CD31 (green), with 4 ¶,6-diamidino-2-phenylindole (blue) staining the nuclei (Fig. 1D) . The results showed that GRP78 was intensely positive in glioma specimens, and the vasculature was prominently labeled with CD31. The merged images validated that GRP78 was highly expressed in both the tumor vasculature and glioma cells. By contrast, normal brain tissues exhibited CD31-positive (green) blood vessels but minimal staining for GRP78 (red; Fig. 1D ). Merged images confirmed negligible GRP78 expression in normal brain and vasculature. These data show that GRP78 is preferably expressed in the tumor vasculature and tumor cells compared with normal brain.
TuBEC Constitutively Overexpress GRP78 without Concomitant Induction of Other Major UPR Targets
Having observed that GRP78 is elevated in TuBEC, we investigated whether this is the consequence of the constitutive activation of the UPR. Two different TuBEC and BEC samples were analyzed for expression of proteins identifying the activated UPR: ATF4 and CHOP and the XBP-1 spliced variant ( Fig. 2A) . BEC treated with thapsigargin (30 nmol/L) for 24 h served as the positive control for ER stress and UPR activation. Our results showed that ATF4 expression was absent in TuBEC, although slightly expressed in BEC; moreover, CHOP and XBP-1 (spliced variant) were not detected in either TuBEC or BEC. Quantitative analysis of the Western blots showed the differential expression profile of these UPR components in TuBEC and BEC (Fig. 2B) , highlighting the unique overexpression of GRP78 in TuBEC in contrast to the lack of induction of other major UPR targets.
GRP78 Regulates Chemoresistance in TuBEC
The constitutive overexpression of GRP78 in TuBEC suggested that this protein may confer chemoresistance to these cells. To test this, the sensitivities of TuBEC and BEC to chemotherapeutic agents were compared. Cells were treated with the topoisomerase II inhibitor etoposide (1-50 Amol/L) or DMSO (vehicle; 0.1%) for 72 h and analyzed for cytotoxicity using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. At 50 Amol/L etoposide, >60% of BEC died, whereas no significant cell death was observed with TuBEC ( Fig. 3A) . These results are not a reflection of cell proliferation because the rate of TuBEC replication is low (3). Similar results were obtained using the Cell Death ELISA Assay (data not shown). Thus, TuBEC were highly chemoresistant compared with BEC.
To determine the effects of reducing GRP78 expression, TuBEC were infected with lentivirus expressing control siRNA (siCtrlA) or siRNA specifically targeted against human GRP78 (siGRP78A). Five days after infection, cell preparations were analyzed for GRP78 protein expression using immunostaining. As shown in Fig. 3B , GRP78 protein was reduced by siGRP78A; no significant change in GRP78 expression was observed with siCtrlA compared with uninfected TuBEC (Fig. 1A) . GRP78 protein levels remained low for at least three passages (21 days; data not shown). If GRP78 confers drug resistance to TuBEC, then knockdown of this protein should overcome resistance. To test this, TuBEC cultures were infected with lentivirus expressing siGRP78A or siCtrlA. Five days after infection, cultures were left untreated (medium) or treated with CPT-11 (100 Amol/L), etoposide (50 Amol/L), or temozolomide (300 Amol/L) for another 7 days and then analyzed for cytotoxicity. We observed that whereas untreated TuBEC were relatively resistant to these drugs (<10% cell death), TuBEC infected with siGRP78A exhibited a significant increase (P < 0.01) in cytotoxicity with each drug tested (Fig. 3C) ; significance was determined by comparing TuBEC infected with siGRP78 with TuBEC infected with siControl. It was noted that endothelial cells infected with siControl and treated with CPT-11 and etoposide exhibited significantly more cell death than medium alone (P < 0.05); this increase is likely due to the effects of lentiviral infection in these sensitive cells and therefore of little biological significance. Interestingly, infection with siGRP78A alone, without drug treatment, did not increase cell death compared with infection with control siRNA, suggesting that decreased GRP78 does not induce spontaneous cytotoxicity within this treatment period.
GRP78 siRNA Induces Caspase-Dependent Cell Death in TuBEC
To eliminate potential ''off-target'' effects of siRNA to GRP78, cytotoxicity measurements were confirmed in TuBEC infected with a second siRNA targeted against human GRP78 (siGRP78B); another control siRNA (siCtrlB) was also used (Fig. 4) . The ability of siGRP78B to suppress GRP78 expression in TuBEC was confirmed by immunostaining (Fig. 4A) ; siCtrlB did not reduce staining similar to what was observed previously with siCtrlA. To determine whether the observed cell death induced by reduced GRP78 was caspase dependent, cells were treated with CPT-11, etoposide, or temozolomide in the presence or absence of the caspase inhibitor Q-VDOPH (10 Amol/L) for 7 days. Caspase inhibition blocked cell death with all three drugs (Fig. 4B ). Significance to this and all subsequent experiments was determined by comparing TuBEC infected with siGRP78 with TuBEC infected with siControl. To confirm that GRP78 knockdown induced apoptotic cell death, the terminal deoxynucleotidyl transferase -mediated dUTP nick end labeling assay was done with uninfected TuBEC or TuBEC infected with lentivirus siGRP78B or siCtrlA and treated with etoposide (50 Amol/L; Fig. 4C ). These data showed that TuBEC, with reduced GRP78, became sensitive to apoptotic cell death on drug treatment.
Inhibition of GRP78 Activity by EGCG Enhances Chemosensitivity in TuBEC
To target GRP78 using a small-molecule approach, TuBEC were incubated with EGCG alone or in combination with temozolomide, CPT-11, and etoposide; cytotoxicity was measured after 7 days (Fig. 4D) . Treatment with temozolomide, CPT-11, etoposide, or EGCG alone did not cause TuBEC cell death; however, combining EGCG and temozolomide (35%; P = 0.003), EGCG and CPT-11 (46%; P = 0.005), or EGCG and etoposide (49%; P = 0.001) caused significant cell death. Significance was calculated as EGCG alone compared with EGCG with drug. These data imply that small-molecule inhibitors such as EGCG, capable of inhibiting GRP78 activity, can be used in combination therapy to increase TuBEC chemosensitivity.
Overexpression of GRP78 Causes Drug Resistance in Normal Endothelial Cells
To determine whether GRP78 overexpression is a key contributing factor to drug resistance in endothelial cells, BEC, were immunostained with anti-GRP78 antibody. The red precipitate designates positive staining; hematoxylin was used as the nuclear stain. B. Intensity of immunostaining from 20 specimens was quantitated: 0 = no staining; 4 = intense staining. *, P < 0.001, significance between groups. C. Two representative samples of TuBEC and BEC were subjected to Western blot analysis. The relative GRP78 protein expression levels, after normalization to h-actin level, were plotted below. D. Cryostat sections of glioma tissues (top ) or normal brain tissues (bottom ) were stained with anti-GRP78 antibody (red), anti-CD31 antibody (green ), and 4 ¶,6-diamidino-2-phenylindole (DAPI ; blue ) nuclear staining; the images were merged in the last panel. Arrows, blood vessels. Bar, 100 Am.
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which normally express low levels of GRP78 and are sensitive to chemotherapeutic agents, were left uninfected or infected with lentivirus expressing either green fluorescent protein (GFP) or GRP78. After 5 days, BEC infected with the latter exhibited an overexpression of GRP78 (Fig. 5A ). BEC were then treated with etoposide (50 Amol/L; Fig. 5B ) or CPT-11 (100 Amol/L; Fig. 5C ), for 5 or 7 days, and tested for cytotoxicity. After 7 days, GRP78 overexpression in BEC provided significant protection against both etoposide (P = 0.008) and CPT-11 (P = 0.046). Cell death data for BEC infected with GRP78 were compared with BEC infected with GFP. To determine whether EGCG can reverse the resistance acquired by BEC infected with GRP78, these cells were treated with EGCG (40 Amol/L) and CPT-11 (100 Amol/L) for 7 days. As shown in Fig. 5D , in cells overexpressing GRP78, treatment with EGCG significantly (P < 0.007) increased sensitivity of these cells to the drug. It is noted that BEC are intrinsically resistant to temozolomide; therefore, protection from cell death by GRP78 could not be assessed with this agent (data not shown).
Discussion
We previously showed that TuBEC are more chemoresistant to drugs compared with BEC (3), although the mechanism of chemoresistance is unknown. Uncovering novel mechanisms for this chemoresistant nature is critical for eradicating residual tumor, which remains a major challenge in cancer therapy. GRP78 has been reported to suppress stress-induced apoptosis through multiple mechanisms (9-13). Further, there is considerable evidence that GRP78 confers drug resistance in a variety of human tumors, including gliomas (8, 9, 13) . The data presented here show that the glioma vasculature constitutively overexpresses GRP78, and this overexpression confers chemoresistance to these tumor-associated endothelial cells.
Induction of GRP78 in cells is often indicative of ER stress and the activation of the UPR (5). To determine whether this is the case in TuBEC, these cells were analyzed for specific proteins identifying UPR activation, such as the induction of CHOP and ATF4, which are downstream targets of the PERK pathway, and the formation of the XBP-1 spliced variant, which results from activation of the IRE-1 pathway (15). Our studies revealed that these other major UPR targets are not induced in TuBEC. Thus, the constitutive overexpression of GRP78 in TuBEC raises the interesting possibility that novel mechanisms independent of the UPR selective for GRP78 induction occur in TuBEC. This could involve genetic as well as epigenetic changes as part of the adaptive mechanisms of TuBEC to survive in the tumor microenvironment. On the other hand, GRP78 overexpression is known to suppress UPR signaling pathways (16, 17) . Thus, it is also possible that TuBEC are subject to ER stress; however, the elevated levels of cytoprotective GRP78 in these cells suppress the induction of the other branches of the UPR. Future studies will address these interesting issues.
What is the consequence of GRP78 overexpression of TuBEC in clinical settings? We show in this study that reducing GRP78 caused TuBEC sensitization to temozolomide, CPT-11, and etoposide, drugs used in treating gliomas and other tumors (18) . These agents have different mechanisms of action but are predominantly directed against proliferating cells. Etoposide is a topoisomerase II inhibitor, which also disrupts mitochondrial activity (19) . Previously, it has been shown that etoposide induces the activation of caspase-7 in Chinese hamster ovary cells and overexpression of GRP78, which colocalizes with caspase-7 in the perinuclear region, suppresses this activation (10) . In TuBEC cells, we also observed that GRP78 colocalized with caspase-7 and this could explain, in part, the protective effect of GRP78 against etoposide in these cells (data not shown). Temozolomide acts as a DNAmethylating agent (20) . CPT-11 (irinotecan) inhibits the religation step of topoisomerase I -mediated DNA cleavages (21) . TuBEC cultures have a low proliferation rate, which is not increased with lentiviral infection (data not shown). Our studies show that drugs, which normally act on replicating cells, will also cause cytotoxicity in these low-proliferating TuBEC when the cytoprotective effects of GRP78 are reduced. These data suggest that GRP78 is an effective target for sensitizing both proliferating and nonproliferating cells to drugs.
The direct role of GRP78 in tumor formation, progression, and angiogenesis has been shown in xenograft models in syngeneic mice and in transgene-induced tumor developed in the heterozygous Grp78 mice, which express reduced levels of GRP78 (22, 23) . These in vivo data showed that reducing GRP78 protein expression resulted in inhibition of tumor cell proliferation, an increase in tumor cell apoptosis, as well as diminished microvessel density. This implies that drugs that target GRP78 expression and/or activity could complement conventional cancer therapy to eliminate residual tumor. Recently, several compounds have been discovered to be GRP78 antagonists (8); they have anticancer activity and work in synergy with chemotherapeutic drugs to reduce tumor growth (14, 24) . As proof of principle, we showed that EGCG, which binds to the ATP-binding domain of GRP78 and thereby blocks its function, was effective in chemosensitizing TuBEC. Of concern was that combination treatment, especially with temozolomide, drug of choice for glioma treatment, may have deleterious effects on the normal vasculature; however, confluent cultures of normal endothelial cells proved to be relatively insensitive to the effects of temozolomide and EGCG together (data not shown). In parallel studies, we have also observed that siRNA against GRP78 as well as EGCG enhanced the sensitivity of glioma cells to chemotherapeutic agents used in this study (13) . Collectively, these results show that decreasing GRP78 protein expression or blocking its activity would significantly enhance both TuBEC and glioma susceptibility to currently available chemotherapeutic agents, thereby eliminating both the tumor and its supplying vasculature.
GRP78 is predominantly expressed as an intracellular protein residing in the ER lumen; however, several experimental approaches indicate that GRP78 is also expressed on the tumor cell surface and that normal endothelial cells when stimulated with growth factors enhance cell surface GRP78 expression (8, (25) (26) (27) . Interestingly, Kringle 5, a ligand binding to surface GRP78, can block endothelial cell migration and mediate cell death (26, 28) . These studies predict that in the abnormally stressful tumor environment, tumor-associated endothelial cells are likely to express GRP78 on the cell surface, and this protein may regulate cell death (26) ; our studies are consistent with this notion, although localization of GRP78 in tumor endothelial cells remains to be established. Identifying mechanisms of drug resistance in TuBEC is essential for appropriate, long-term therapy with the goal of targeting the tumor vasculature as well as tumor cells. Our discovery of the relationship between GRP78 and TuBEC chemoresistance will open new directions in antivascular therapies for gliomas and other cancers.
Materials and Methods
Cell Culture
Endothelial cells were isolated from normal human brain tissue or human glioma tissue as previously described (3, 4) . These specimens were not obtained from the same patient. Technologies), and 10% FCS (Omega Scientific). Purity of endothelial cells was analyzed by immunostaining for the following specific endothelial cell markers: CD31/PECAM-1 (Santa Cruz Biotechnology), von Willebrand factor (DAKO), and CD105/endoglin (Santa Cruz Biotechnology); cells were >98% positive for these markers. Cells were also analyzed for the astrocyte/glioma marker, glial fibrillary acidic protein (DAKO), and the macrophage/microglia marker CD11b (Immunotech) to rule out other cell types; endothelial cell cultures used were negative for both these proteins. All experiments were done on subconfluent (60-80%) BEC and TuBEC cultures and on cells between passages 4 to 6 only.
Immunostaining
Cytocentrifuge cell preparations and cryostat tissue sections were stained as previously described (3, 4) . Briefly, cell preparations were fixed in acetone; tissue sections were fixed in 4% paraformaldehyde. Specimens were then stained with rabbit polyclonal anti-GRP78 antibody (1:100; H129; Santa Cruz Biotechnology) for 16 h followed by the secondary biotinylated goat anti-rabbit antibody (1:400; Vector Laboratories). Subsequently, the samples were treated with the avidin-biotin peroxidase complex (Vector Laboratories) followed by aminoethylcarbazol substrate kit (Vector Laboratories), which provided the red precipitate at the site of the antigen. Samples were counterstained with hematoxylin, the blue nuclear stain. The red precipitate identifies positive staining. Staining controls included using isotype-matched serum in place of the primary antibody and staining known negative cell preparations. For double immunofluorescence, tissues were incubated with both rabbit anti-GRP78 and mouse monoclonal anti-human CD31/PECAM-1 antibodies (1:100; R&D Systems) for 16 h and subsequently stained with Texas red -labeled anti-rabbit antibody and fluorescein (green)-labeled anti-mouse antibody (Vector Laboratories). Nuclei were identified using 4 ¶,6-diamidino-2-phenylindole (blue)-containing mounting medium (Vector Laboratories). Staining controls included isotype-matched serum.
Western Blot Analysis
Endothelial cells were lysed in buffer containing 20 mmol/L Tris-base, 300 mmol/L NaCl, 5 mmol/L EDTA, 0.1% SDS, 1% deoxycholate, 1% Triton X-100, and protease inhibitor cocktail at 1:100 dilution (Sigma-Aldrich). About 50 to 80 Ag of protein lysate were subjected to 10% SDS-PAGE and electrotransferred onto nitrocellulose membranes. The primary antibodies used for Western blots were rabbit anti-GRP78 (H129; 1:500), monoclonal anti-h-actin (1:5,000), rabbit anti -glyceraldehyde-3-phosphate dehydrogenase (FL-335; 1:5,000), monoclonal anti-CHOP (1:500), rabbit anti-ATF4 (1:1,000), and rabbit XBP-1 (M-186; 1:1,000), all purchased from Santa Cruz Biotechnology. Protein bands were either detected by chemiluminescence using the SuperSignal substrate (Pierce) and analyzed using a phosphorimager (Hope MicroMax, Freedom Imaging) or quantitated by densitometry (Quantitation One 4.2.1, Bio-Rad).
MTT Cell Viability Assay
Cells were plated in triplicate (3 Â 10 3 per well; 100 AL/well) into 96-well plates coated with 1% gelatin and treated with etoposide (Calbiochem), temozolomide (Schering-Plough), or CPT-11 (Pharmacia). The MTT assay was done according to the manufacturer's instructions (Sigma-Aldrich). Percent cell viability was calculated relative to vehicle-treated controls.
Cell Death ELISA
Endothelial cells were treated with drugs or the caspase inhibitor Q-VDOPH (Calbiochem) or EGCG (Sigma-Aldrich) and then assayed using the Cell Death Detection ELISA Plus kit (Roche Diagnostics) according to the manufacturer's instructions. Percent death was calculated based on 100% positive cell death control.
Apoptosis Assay
The ApopTag In Situ Apoptosis Detection kit (Chemicon International, Inc.) was done according to the manufacturer's protocol. A. BEC were uninfected (UI) and infected with lentivirus expressing either the control GFP or GRP78. Five days after infection, cells were harvested for Western blot analysis and probed for GRP78 and glyceraldehyde-3-phosphate dehydrogenase. B. BEC, uninfected or infected with lentivirus GFP or GRP78, were treated with etoposide (50 Amol/L) for 0, 5, or 7 d. At the termination of the experiments, cell death was analyzed using the Cell Death ELISA Assay. Percent death was calculated based on total cell death control. Statistical comparisons were made between BEC/GRP78 and BEC/GFP on day 7. *, P < 0.05. C. BEC, uninfected or infected with lentivirus GFP or GRP78, were treated with CPT-11 (100 Amol/L) for 0, 5, or 7 d. At the termination of the experiments, cell death was analyzed using the Cell Death ELISA Assay. Statistical comparisons were made between BEC/GRP78 and BEC/GFP on day 7. *, P < 0.05. D. BEC, uninfected or infected with lentivirus GFP or GRP78, were either untreated or treated with EGCG (40Amol/L) alone, CPT-11 (100 Amol/L) alone, or EGCG (40 Amol/L) plus CPT-11 (100 Amol/L) for 7 d. At the termination of the experiments, cell death was analyzed using the Cell Death ELISA Assay. Statistical comparisons were made between BEC/ GRP78 treated with CPT-11 and BEC/GRP78 treated with CPT-11 and EGCG. *, P < 0.05.
Lentiviral Construct
The sequences of the siRNA against human GRP78 are as follows: siGRP78A, 5 ¶-GGAGCGCAUUGAUACUAGAUU-3 ¶; siGRP78B, 5 ¶-AAGAAAAGCUGGGAGGUAAAC-3 ¶. The sequences of control siRNA are as follows: siCtrlA, 5 ¶-GGA-GAAGAAUAGCAACGGUAA-3 ¶; siCtrlB, 5 ¶-AAGGUG-GUUGUUUUGUUCAUU-3 ¶. Their subcloning into lentiviral constructs has been previously described (29) . For construction of lentivirus expressing GRP78, full-length human GRP78 was prepared by reverse transcription of total HEK293T RNA followed by a two-step PCR amplification and subcloning into the BamH1/XhoI sites of pcDNA3 (Invitrogen) to yield pcDNA3-hGRP78. Nonreplicating lentiviral vectors coexpressing bicistronic human GRP78 and EGFP linked via the encephalomyocarditis virus internal ribosomal entry site were produced using the pLenti6/V5-D-TOPO and ViraPower Lentivirus Expression system supplied by Invitrogen. Initially, EGFP (Clontech) was inserted into the cytomegalovirus-driven expression cassette by TOPO cloning. After the viability of this construct was established, the parent construct was modified. The human GRP78 gene digested from pcDNA3/h78 using XbaI and XhoI was ligated into pLenti6/EGFP between the cytomegalovirus promoter and the EGFP gene. Next, an insert encoding the encephalomyocarditis virus internal ribosomal entry site was generated by PCR from pIRES-EGFP (Clontech) and subcloned into the XhoI/AgeI sites of pLenti6/huGRP78 EGFP. The internal ribosomal entry site sequence was inserted between the human GRP78 gene and the EGFP, allowing hGRP78 expression to be monitored by EGFP fluorescence. The manufacturer's manual was followed for TOPO cloning and production of viral particles. For infection, 10 4 cells were plated in six-well dishes and infected with lentivirus at titers of 5 Â 10 6 transducing units/mL. Infected cells were monitored for GFP under the fluorescent microscope. Cells were used when cultures were 100% GFP positive.
Statistical Analysis
Values are presented as mean and SE. Statistical significance was evaluated using the Student's two-tailed t test, with P < 0.05 considered significant.
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